TREATMENT OF AUTOIMMUNE DISEASES IN PATIENT SUFFERING FROM INADEQUATE RESPONSE TO TNF-ALPHA INHIBITOR Russian patent published in 0 - IPC A61K39/395 A61P37/02 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, particularly to immunology, and concerns treatment of rheumatoid arthritis associated with inadequate response to TNF-alpha inhibitor. The treatment is ensured by intravenous introduction of antibodies bound with CD20, particularly humanised 2H7v16, containing variable domains presented with SEQ ID Nos. 1 and 2. Antibodies are injected intravenously in dosage 1000 mg twice.

EFFECT: effective treatment of arthritis associated with inadequate response to TNF-alpha inhibitor due to introduction regimen developed by the applicant, extension of range of medical products for treatment of said pathology.

2 cl, 1 tbl, 1 ex